This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2005 May;2(5):236-7.

doi: 10.1038/ncponc0168.

Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?

Hiroshi Miyamoto¹, Edward M Messing, Chawnshang Chang

Affiliations

PMID: 16264955
DOI: 10.1038/ncponc0168

Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?

Hiroshi Miyamoto et al. Nat Clin Pract Oncol. 2005 May.

. 2005 May;2(5):236-7.

doi: 10.1038/ncponc0168.

Authors

Hiroshi Miyamoto¹, Edward M Messing, Chawnshang Chang

Affiliation

¹ Department of Pathology, University of Rochester Medical Center, NY 14642, USA.

PMID: 16264955
DOI: 10.1038/ncponc0168

No abstract available

PubMed Disclaimer

Similar articles

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ, Brandt D, Schour L, Hill DR. Demanes DJ, et al. Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277. Am J Clin Oncol. 2009. PMID: 19398902
High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J. Vargas C, et al. Prostate Cancer Prostatic Dis. 2006;9(3):245-53. doi: 10.1038/sj.pcan.4500882. Epub 2006 Jun 20. Prostate Cancer Prostatic Dis. 2006. PMID: 16786040
A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
Ciezki JP, Klein EA, Angermeier K, Ulchaker J, Chehade N, Altman A, Mahadevan A, Reddy CA. Ciezki JP, et al. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1347-50. doi: 10.1016/j.ijrobp.2004.05.067. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590163
Prostate cancer: non-metastatic.
Wilt T. Wilt T. Clin Evid. 2002 Jun;(7):812-23. Clin Evid. 2002. Update in: Clin Evid. 2003 Jun;(9):973-85. PMID: 12230707 Updated. Review. No abstract available.
Prostate cancer (non-metastatic).
Wilt T. Wilt T. Clin Evid. 2003 Jun;(9):973-85. Clin Evid. 2003. Update in: Clin Evid. 2003 Dec;(10):1023-38. PMID: 12967402 Updated. Review. No abstract available.

See all similar articles

Cited by

Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.
Tang D, He J, Dai Y, Geng X, Leng Q, Jiang H, Sun R, Xu S. Tang D, et al. Cancer Gene Ther. 2022 May;29(5):543-557. doi: 10.1038/s41417-021-00332-6. Epub 2021 Apr 14. Cancer Gene Ther. 2022. Retraction in: Cancer Gene Ther. 2023 Oct;30(10):1442. doi: 10.1038/s41417-023-00669-0. PMID: 33854217 Retracted.
The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module.
Chen K, Wu K, Jiao X, Wang L, Ju X, Wang M, Di Sante G, Xu S, Wang Q, Li K, Sun X, Xu C, Li Z, Casimiro MC, Ertel A, Addya S, McCue PA, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG. Chen K, et al. Cancer Res. 2015 May 15;75(10):1992-2004. doi: 10.1158/0008-5472.CAN-14-0611. Epub 2015 Mar 13. Cancer Res. 2015. PMID: 25769723 Free PMC article.
Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W, Li T, Xie Z, Zhao J, Zhang Y, Ruan Y, Han B. Wang W, et al. J Transl Med. 2024 Jan 14;22(1):57. doi: 10.1186/s12967-023-04807-y. J Transl Med. 2024. PMID: 38221616 Free PMC article.
Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.
Xu H, Sun Y, Huang CP, You B, Ye D, Chang C. Xu H, et al. Cancers (Basel). 2020 Mar 30;12(4):831. doi: 10.3390/cancers12040831. Cancers (Basel). 2020. PMID: 32235588 Free PMC article.
Infiltrating bone marrow mesenchymal stem cells (BM-MSCs) increase prostate cancer cell invasion via altering the CCL5/HIF2α/androgen receptor signals.
Luo J, Lee SO, Cui Y, Yang R, Li L, Chang C. Luo J, et al. Oncotarget. 2015 Sep 29;6(29):27555-65. doi: 10.18632/oncotarget.4515. Oncotarget. 2015. PMID: 26342197 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information